Robert Mittendorff, MD

Dr. Mittendorff is a General Partner and Head of Healthcare who leads investments at B Capital in venture and growth opportunities in the sector. Previously, he was at Norwest Venture Partners for nearly a decade as a Partner and Co-Head of Healthcare. He has been involved in investments and associated exits with public equity value or acquisition value that exceeds a total of $10B. He is a board-certified emergency physician and former public company operating executive.

He has served on the boards of Impel Neuropharma, Avalyn Pharma, Qventus, and VisitPay, TigerConnect, Neocis, and was a board observer at Talkspace, Omada, and Route92. He was a board member at Silk Road Medical (SILK), iCardiac (acq. by eResearch), and Telcare (acq. by BioTelemetry). Prior to his career in venture capital, Dr. Mittendorff was an executive officer and the Vice President of Marketing and Business Development at Hansen Medical Inc. (Nasdaq: HNSN), acquired by Auris/JNJ.  He earned a Harvard M.D., trained at Stanford in Emergency Medicine, and received his M.B.A. from Harvard Business School and his B.S. in biomedical engineering from Johns Hopkins (high hon).

Daniel Janse

Daniel Janse is a Director at Northpond Ventures and leads the firm’s work in biotechnologies. Previously, Daniel was the Chief Operating Officer and Chief Business Officer at Arbor Biotechnologies, where he led scientific and general operations, business development, program and alliance management, and corporate development and strategy. Prior to Arbor, Daniel served in leadership positions in the U.S. and Europe at Juno Therapeutics, Johnson & Johnson Innovation Center, Inventages Venture Capital, and McKinsey & Company. Additionally, he was a Presidential Postdoctoral Fellow at Novartis Institutes for Biomedical Research in Austria. Daniel holds a Ph.D. from Harvard University, where he trained in the laboratory of Dr. George Church in the Department of Genetics. He earned a B.S. and B.A. with honors in biochemistry and economics from Brown University where he was an Oettinger National Scholar.

Lee Cooper

Lee is Director of Venture Investments with Leaps by Bayer, where he aims to contribute to new biotechnologies that enable patients and communities to live healthier lives. Prior to joining Leaps, Lee was Entrepreneur-in-Residence with RA Capital and founder of Enlight Bio, a biotech focused on genetic disease. Previously, Lee worked in corporate development for Moderna Therapeutics, leading and supporting transactions, financings, and partnerships to develop novel therapeutics and vaccines.

In addition to Triumvira, Lee serves on the Boards of Pyxis Oncology and FutuRx, and is a Board Observer for Recursion Pharmaceuticals and Century Therapeutics. He is the founder of the Institute for Genetic Disease Prevention and has written on innovation and ethics for Wired, Slate, Neo.Life, and STAT News. Lee earned his J.D. and M.B.A. from Columbia University where he was a Stone Scholar and currently lectures on topics in biotechnology, and graduated with honors from Dartmouth College with an A.B. in Religion and Public Policy.

Brian Bloom

Brian Bloom is a co-founder of Bloom Burton & Co. and serves as the firm’s Chairman and Chief Executive Officer.

Brian serves on the Board of Directors of Triumvira Immunologics, Appili Therapeutics, Satellos Bioscience, and Qing Bile Therapeutics. Brian is also on the Faculty of Science Dean’s Advisory Board at McMaster University. Brian was formerly the Chairman of the Board of Grey Wolf Animal Health, a member of the Life Sciences Advisory Board at the National Research Council of Canada and on the Boards of BIOTECanada and the Baycrest Foundation.

Before co-founding Bloom Burton in 2008, Brian spent six years at Dundee Securities in the healthcare and biotechnology institutional sales and equity research groups. Brian started his career at New York-based investment banking firms SCO Financial Group and Molecular Securities. Brian received an Honors Bachelor of Science in Biochemistry from McMaster University and subsequently studied at the Mount Sinai Graduate School for Biological Sciences of New York University, with a focus in molecular endocrinology and biophysics. Brian is the proud recipient of the McMaster University 2017 Distinguished Alumni Award in Science.

Elizabeth Williams

Elizabeth Williams is the Chief Financial Officer of Medicenna Therapeutics Corp., a clinical-stage immunotherapy company, where she has responsibility for all corporate finance and accounting functions. Ms. Williams joined Medicenna as a private company and led the public listings onto the TSX and subsequently NASDAQ. She has more than 15 years of experience in biotech, working with publicly listed entities in both Canada and the United States, and has played an integral role in raising more than $150 million in financings during this period.

Previously, Ms. Williams was the Vice President of Finance and Administration at Aptose Biosciences, Inc. a biotechnology company listed on both the TSX and NASDAQ, and began her career at Ernst & Young LLP. She is a CPA and CA and received a BBA from Wilfrid Laurier University.

Cynthia (Cindy) Collins

Cynthia Collins served as Chief Executive Officer of Editas Medicine, Inc. (EDIT) from March 2019 to February 2021 and served as a member of the board of directors of Editas Medicine from December 2018 to February 2021. Previously, Ms. Collins served as Chief Executive Officer of Human Longevity Inc. and Chief Executive Officer/General Manager of General Electric’s Healthcare Cell Therapy and Lab Businesses and GE’s Clarient Diagnostics. Prior to GE, Ms. Collins served as CEO of GenVec (GNVC), a vaccine and gene therapy company and before that, she served as Group Vice President, Cellular Analysis Business of Beckman Coulter.

Ms. Collins received her BS degree in Microbiology from the University of Illinois, Urbana and her MBA from The University of Chicago Booth School of Business. She is currently a member of the boards of Certara (CERT), Poseida Therapeutics (PSTX) and DermTech, Inc. (DMTK).

Jürgen Eckhardt

Jürgen Eckhardt is SVP and Head of Leaps by Bayer, which is the strategic venture capital unit of Bayer. The mission of Leaps is to invest in breakthrough technologies and disruptive business models in the areas of healthcare and agriculture. Jürgen is currently a board member of BlueRock, Joyn Bio, Dewpoint, Khloris, Oerth Bio, Immunitas, and eGenesis. Before joining Bayer in 2016, Jürgen Eckhardt was head of the venture capital franchise at Bellevue Asset Management in Switzerland.

Previously, he was a management consultant and Associate Partner with McKinsey & Co. in Zürich and New York and a member of the Healthcare Leadership Team. He began his career as a radiologist at the University Hospital of Basel, Switzerland. Jürgen received his M.D. from the University of Basel and his MBA from INSEAD in Fontainebleau, France.

Scott Smith

Mr. Smith has 30 years of biotechnology and pharmaceutical industry experience. Scott is currently serving as President of BioAtla, a company focused on the development of conditionally active biologics (CABs) for the treatment of solid tumor cancers.

In his ten years at Celgene from 2008-2018 his leadership role expanded from Vice President of Global Marketing for Inflammation & Immunology, to Global Head of that division, to President of the Inflammation & Immunology Franchise to his appointment in 2017 as Celgene’s President and Chief Operating Officer. With a particular emphasis and interest in immunology, Mr. Smith drove the growth of Celgene’s Inflammation and Immunology division from 13 to more than 1,300 people worldwide and oversaw the clinical development, global registration and commercial success of the blockbuster drug Otezla.

Mr. Smith’s prior experience at Pharmacia (acquired by Pfizer) and at Biovail included global responsibility for sales and marketing, creating and executing commercial and business development strategies and contributing to regulatory and clinical development strategies.

Mr. Smith also serves on the board of directors of Titan Pharmaceuticals, Triumvira Immunologics and Springbank Pharmaceuticals.

Mr. Smith received both his BSc degree in Chemistry and Biology and his HBSc degree in Pharmacology and Toxicology from the University of Western Ontario and his Masters of International Business Management from the American Graduate School of International Management (Thunderbird).

Paul Lammers

Paul Lammers, MD, MSc, joined Triumvira Immunologics as President and CEO in January 2018. Before Triumvira, Dr. Lammers served as President & CEO at Mirna Therapeutics, for which company he raised $160 million through venture capital and Federal and State government funding, as well as a public listing on NASDAQ. Previously, he served as Chief Medical Officer and Head of US Product Development for EMD Serono.

During his early industry tenure, Dr. Lammers also held various executive/senior management positions in clinical development, medical and regulatory affairs, at different pharmaceutical companies, as well as at small public and privately held biotech companies. Dr. Lammers serves as Lead Independent Director for publicly-traded Salarius Pharmaceuticals, and as Director for a private biotech company, Immunomet.